Tridek-One

📍 Paris, France🗓 Founded 2018👥 14 employees💰 Last funded Sep 2022
Biotechnology Research🌐 tridekone.com
Website LinkedIn
Tridek-One is a spin-off from Inserm that develops first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases. The company primarily focuses on the research and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance. Anti-CD31 agonistic mAbs have the potential to provide targeted immunomodulatory activity with a favorable safety profile in diseases with high unmet clinical need. Tridek-One has initiated a discovery program which targets another ITIM receptor, fully leveraging its understanding of inhibitory checkpoint receptor modulation and agonistic monoclonal antibodies engineering. Our company is financed by leading European investors and led by an experienced management team.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Tridek-One?
Tridek-One has 1 investors on record on gritt.io, 1 mid-stage.
When did Tridek-One last raise funding?
The most recent investment in Tridek-One recorded on gritt.io was in September 2022.
When was Tridek-One founded?
Tridek-One was founded in 2018.
What industry is Tridek-One in?
Tridek-One operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Tridek-One based?
Tridek-One is headquartered in Paris, France.